Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:727783a66712f0c28664b2242182af99]
Measured by the frequency of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, Grade 3 or 4 AEs, deaths, laboratory abnormalities and clinically relevant electrocardiogram (ECG) changes from baseline
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:727783a66712f0c28664b2242182af99]
Measured by the frequency of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, Grade 3 or 4 AEs, deaths, laboratory abnormalities and clinically relevant electrocardiogram (ECG) changes from baseline
Bio2RDF identifier
727783a66712f0c28664b2242182af99
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:727783a66712f0c28664b2242182af99
measure [clinicaltrials_vocabulary:measure]
Safety and tolerability of multiple daily doses of BMS-986115
time frame [clinicaltrials_vocabulary:time-frame]
Up to 30 days after the last dose of study medication (approximately 18 months)
description
Measured by the frequency of a ...... am (ECG) changes from baseline
identifier
clinicaltrials_resource:727783a66712f0c28664b2242182af99
title
Safety and tolerability of mul ...... tion (approximately 18 months)
@en
type
label
Safety and tolerability of mul ...... 783a66712f0c28664b2242182af99]
@en